Exelixis (EXEL) 10-Q 31 Jul 14 2014 Q2 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	6 Months Ended
	Jun. 30, 2014	Jul. 24, 2014
Document And Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Jun-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q2	'
Trading Symbol	'exel	'
Entity Registrant Name	'EXELIXIS, INC.	'
Entity Central Index Key	'0000939767	'
Entity Filer Category	'Large Accelerated Filer	'
Current Fiscal Year End Date	'--01-02	'
Entity Common Stock, Shares Outstanding	'	195,109,967

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$147,340	$103,978	[1]
Short-term investments	86,177	138,475	[1]
Short-term restricted cash and investments	12,214	12,213	[1]
Trade and other receivables	5,034	3,941	[1]
Inventory	3,026	2,890	[1]
Prepaid expenses and other current assets	4,792	5,112	[1]
Total current assets	258,583	266,609	[1]
Long-term investments	95,513	144,299	[1]
Long-term restricted cash and investments	10,781	16,897	[1]
Property and equipment, net	4,052	4,910	[1]
Goodwill	63,684	63,684	[1]
Other assets	8,022	6,888	[1]
Total assets	440,635	503,287	[1]
Current liabilities:	'	'
Accounts payable	4,638	9,345	[1]
Accrued clinical trial liabilities	41,367	34,958	[1]
Accrued compensation and benefits	9,856	12,797	[1]
Other accrued liabilities	15,859	13,116	[1]
Current portion of convertible notes	94,207	10,000	[1]
Current portion of loans payable	1,077	1,762	[1]
Current portion of restructuring	3,726	4,425	[1]
Deferred revenue	1,127	1,450	[1]
Total current liabilities	171,857	87,853	[1]
Long-term portion of convertible notes	173,635	255,147	[1]
Long-term portion of loans payable	80,055	80,328	[1]
Long-term portion of restructuring	6,743	9,047	[1]
Other long-term liabilities	5,102	4,674	[1]
Total liabilities	437,392	437,049	[1]
Commitments	'	'	[1]
Stockholders' Equity:	'	'
Preferred stock	0	0	[1]
Common stock, $0.001 par value; 400,000,000 shares authorized; issued and outstanding: 195,088,645 and 184,533,651 shares at June 30, 2014 and December 31, 2013, respectively	195	184	[1]
Additional paid-in capital	1,649,662	1,564,670	[1]
Accumulated other comprehensive income	177	146	[1]
Accumulated deficit	-1,646,791	-1,498,762	[1]
Total stockholders’ equity	3,243	66,238	[1]
Total liabilities and stockholders' equity	$440,635	$503,287	[1]
[1]	The condensed consolidated balance sheet as of December 31, 2013 has been derived from the audited financial statements as of that date.

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Statement of Financial Position [Abstract]	'	'
Common stock, par value, in dollars per share	$0.00	$0.00
Common stock, shares authorized	400,000,000	400,000,000
Common stock, shares issued	195,088,645	184,533,651
Common stock, shares outstanding	195,088,645	184,533,651

Condensed_Consolidated_Stateme

Condensed Consolidated Statements Of Operations (USD $)	3 Months Ended		6 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Revenues:	'	'	'	'
Net product revenues	$6,562	$4,043	$11,467	$5,899
License and contract revenues	0	7,813	0	15,626
Total revenues	6,562	11,856	11,467	21,525
Operating expenses:	'	'	'	'
Cost of goods sold	477	285	786	565
Research and development	50,976	49,077	105,823	81,812
Selling, general and administrative	16,466	13,180	31,157	23,725
Restructuring charge	331	609	377	728
Total operating expenses	68,250	63,151	138,143	106,830
Loss from operations	-61,688	-51,295	-126,676	-85,305
Other income (expense), net:	'	'	'	'
Interest income and other, net	359	373	2,490	711
Interest expense	-12,081	-11,239	-23,843	-22,296
Total other income (expense), net	-11,722	-10,866	-21,353	-21,585
Net loss	($73,410)	($62,161)	($148,029)	($106,890)
Net loss per share, basic and diluted, in dollars per share	($0.38)	($0.34)	($0.77)	($0.58)
Shares used in computing basic and diluted net loss per share, in shares	194,929	183,981	193,323	183,861

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Comprehensive Loss (USD $)	3 Months Ended				6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014		Jun. 30, 2013		Jun. 30, 2014		Jun. 30, 2013
Statement of Comprehensive Income [Abstract]	'		'		'		'
Net loss	($73,410)		($62,161)		($148,029)		($106,890)
Other comprehensive income (loss)	24	[1]	-365	[1]	31	[1]	-171	[1]
Comprehensive loss	($73,386)		($62,526)		($147,998)		($107,061)
[1]	Other comprehensive income (loss) consisted solely of unrealized gains or losses, net on available for sale securities arising during the periods presented. There were no reclassification adjustments to net loss resulting from realized gains or losses on the sale of securities and there was no income tax expense related to other comprehensive income during those periods.

Condensed_Consolidated_Stateme2

Condensed Consolidated Statements of Cash Flows (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014		Jun. 30, 2013
Cash flows from operating activities:	'		'
Net loss	($148,029)		($106,890)
Adjustments to reconcile net loss to net cash used in operating activities:	'		'
Depreciation and amortization	1,093		1,628
Stock-based compensation expense	7,740		5,605
Accretion of debt discount	14,316		12,793
Changes in the fair value of warrants	-1,854		0
Other	2,615		3,642
Changes in assets and liabilities:	'		'
Trade and other receivables	-1,093		-1,458
Inventory	-136		-681
Prepaid expenses and other assets	226		224
Accounts payable, accrued compensation, and other accrued liabilities	-4,905		379
Clinical trial liabilities	6,409		8,846
Restructuring liability	-3,003		-3,349
Other long-term liabilities	-479		-374
Deferred revenue	-323		-14,814
Net cash used in operating activities	-127,423		-94,449
Cash flows from investing activities:	'		'
Purchases of property and equipment	-344		-1,402
Proceeds from sale of property and equipment	281		0
Proceeds from maturities of restricted cash and investments	10,777		9,868
Purchase of restricted cash and investments	-4,643		-3,784
Proceeds from maturities of investments	181,258		209,889
Purchases of investments	-82,280		-147,751
Net cash provided by investing activities	105,049		66,820
Cash flows from financing activities:	'		'
Proceeds from issuance of common stock, net	75,646		0
Proceeds from exercise of stock options and warrants	120		22
Proceeds from employee stock purchase plan	928		894
Principal payments on debt	-10,958		-11,582
Net cash provided by (used in) financing activities	65,736		-10,666
Net increase (decrease) in cash and cash equivalents	43,362		-38,295
Cash and cash equivalents at beginning of period	103,978	[1]	170,069
Cash and cash equivalents at end of period	147,340		131,774
Supplemental cash flow disclosure - non-cash financing activity:	'		'
Issuance of warrants in connection with amendment to convertible notes	$2,762		$0
[1]	The condensed consolidated balance sheet as of December 31, 2013 has been derived from the audited financial statements as of that date.

Organization_and_Summary_of_Si

Organization and Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Organization and Summary of Significant Accounting Policies	'
	ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Organization
	Exelixis, Inc. (“Exelixis,” “we,” “our” or “us”) is a biopharmaceutical company committed to developing small molecule therapies for the treatment of cancer. Our two most advanced assets are cabozantinib, our wholly-owned inhibitor of multiple receptor tyrosine kinases, and cobimetinib (GDC-0973/XL518), a potent, highly selective inhibitor of MEK, which we out-licensed to Genentech (a member of the Roche Group) (“Genentech”). We are evaluating cabozantinib in a broad development program, including five ongoing phase 3 pivotal trials. We currently expect top-line results in 2014 from our two phase 3 pivotal trials of cabozantinib in metastatic castration-resistant prostate cancer, and from the overall survival analysis of our phase 3 EXAM pivotal trial of cabozantinib in progressive metastatic medullary thyroid cancer (“MTC”). Genentech is evaluating cobimetinib in a broad development program. On July 14, 2014, we reported positive top-line results from Genentech’s coBRIM study, a phase 3 pivotal trial evaluating cobimetinib in combination with vemurafenib in previously untreated patients with unresectable locally advanced or metastatic melanoma harboring a BRAFV600 mutation.
	We are focusing our development and commercialization efforts primarily on cabozantinib. Cabozantinib was approved by the U.S. Food and Drug Administration (“FDA”), on November 29, 2012, for the treatment of progressive, metastatic MTC, in the United States under the brand name COMETRIQ(R). COMETRIQ became commercially available in the United States in late January 2013. In March 2014, the European Commission approved cabozantinib for the treatment of adult patients with progressive, unresectable locally advanced or metastatic MTC, also under the brand name COMETRIQ. The European Commission granted conditional marketing authorization following a positive opinion from the European Committee for Medicinal Products for Human Use (“CHMP”), issued in December 2013.
	Basis of Consolidation
	The consolidated financial statements include the accounts of Exelixis and those of our wholly-owned subsidiaries. These entities’ functional currency is the U.S. dollar. All intercompany balances and transactions have been eliminated.
	Basis of Presentation
	The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. In our opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of the results of operations and cash flows for the period presented have been included.
	Exelixis adopted a 52- or 53-week fiscal year that generally ends on the Friday closest to December 31st. Fiscal year 2013, a 52-week year, ended on December 27, 2013, and fiscal year 2014, a 53-week year, will end on January 2, 2015. For convenience, references in this report as of and for the fiscal periods ended June 27, 2014 and June 28, 2013, and as of the fiscal year ended December 27, 2013, are indicated as ended June 30, 2014, June 30, 2013, and December 31, 2013, respectively.
	Operating results for the six months ended June 30, 2014 are not necessarily indicative of the results that may be expected for the fiscal year ending January 2, 2015 or for any future period. These financial statements and notes should be read in conjunction with the consolidated financial statements and notes thereto for the year ended December 31, 2013, included in our Annual Report on Form 10-K filed with the SEC on February 20, 2014.
	Segment Information
	We operate as a single reportable segment.
	Use of Estimates
	The preparation of our consolidated financial statements is in conformity with accounting principles generally accepted in the United States which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. On an ongoing basis, management evaluates its estimates including, but not limited to, those related to inventory, revenue recognition, valuation of long-lived assets, certain accrued liabilities including clinical trial accruals and restructuring liability, valuation of warrants, share-based compensation and the valuation of the debt and equity components of our convertible debt at issuance. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.
	Revenue Recognition
	We recognize revenue from the sale of COMETRIQ and from license fees and milestones earned on research and collaboration arrangements. See “Note 1 - Organization and Summary of Significant Accounting Policies” to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2013 for a description of our policies for revenue recognition on research and collaboration agreements. We did not enter into any new collaboration agreements during the six months ended June 30, 2014. See “Note 2 - Research and Collaboration Agreements” to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2013 for a description of our existing collaboration agreements.
	Net Product Revenues
	We recognize revenue when it is both realized or realizable and earned, meaning persuasive evidence of an arrangement exists, delivery has occurred, title has transferred, the price is fixed or determinable, there are no remaining customer acceptance requirements, and collectability of the resulting receivable is reasonably assured. For product sales in the United States, this generally occurs upon shipment of the product to the patient by our distributor. For product sales in Europe, this occurs when our European distribution partner has accepted the product.
	We sell our product, COMETRIQ, in the United States to a specialty pharmacy that benefits from customer incentives and has a right of return. We have a limited sales history and cannot reliably estimate expected returns of the product nor the discounts and rebates due to payors at the time of shipment to the specialty pharmacy. Accordingly, upon shipment to the specialty pharmacy, we record deferred revenue on our Consolidated Balance Sheets. We recognize revenue when the specialty pharmacy provides the product to a patient based on the fulfillment of a prescription. We record revenue using an analysis of prescription data from our specialty pharmacy to ascertain the date of shipment and the payor mix. This approach is frequently referred to as the “sell-through” revenue recognition model. Once the prescription has been provided to the patient, it is not subject to return unless the product is damaged.
	We record revenue at the time our European distribution partner has accepted the product, a method also known as the “sell-in” revenue recognition model.
	Product Sales Discounts and Allowances
	We calculate gross product revenues based on the price that we charge our United States specialty pharmacy and our European distribution partner. We estimate our domestic net product revenues by deducting from our gross product revenues (a) trade allowances, such as discounts for prompt payment, (b) estimated government rebates and chargebacks, and (c) estimated costs of patient assistance programs. We initially record estimates for these deductions at the time we recognize the gross revenue. We update our estimates on a recurring basis as new information becomes available. Our European distribution partner is entitled to receive a project management fee based upon the achievement of a pre-specified revenue goal which, when deemed probable, is ratably accrued as a reduction to gross revenue. See “Note 1 - Organization and Summary of Significant Accounting Policies” to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2013 for a further description of our discounts and allowances.
	Cost of Goods Sold
	Cost of goods sold is related to our product revenues and consisted primarily of a 3% royalty and indirect labor costs, and to a lesser extent, the cost of manufacturing and other third party logistics costs of our product. A significant portion of the manufacturing costs for product sales were incurred prior to regulatory approval of COMETRIQ for the treatment of progressive, metastatic MTC and, therefore, were expensed as research and development costs when those costs were incurred, rather than capitalized as inventory.
	In accordance with our product development and commercialization agreement with GlaxoSmithKline, we are required to pay GlaxoSmithKline a 3% royalty on the Net Sales of any product incorporating cabozantinib, including COMETRIQ. Net Sales is defined in the product development and commercialization agreement generally as the gross invoiced sales price less customer credits, rebates, chargebacks, shipping costs, customs duties, and sales tax and other similar tax payments we are required to make.
	Recently Issued Accounting Pronouncements
	In May 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2014-09, Revenue from Contracts with Customers ("ASU 2014-09"). ASU 2014-09 supersedes the revenue recognition requirements of FASB Accounting Standards Codification ("ASC") Topic 605, Revenue Recognition and most industry-specific guidance throughout the Accounting Standards Codification, resulting in the creation of FASB ASC Topic 606, Revenue from Contracts with Customers. ASU 2014-09 requires entities to recognize revenue in a way that depicts the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. Adoption will be permitted using either a retrospective or modified retrospective approach, and is effective for fiscal years, and interim periods within those years, beginning after December 15, 2016. Early adoption is not permitted. We are currently evaluating the impact of adopting this ASU, inclusive of available transitional methods on our consolidated financial statements and related disclosures.

Restructurings

Restructurings	6 Months Ended
	Jun. 30, 2014
Restructuring Charges [Abstract]	'
Restructurings	'
	RESTRUCTURINGS
	Between March 2010 and May 2013, we implemented five restructurings (referred to collectively as the “Restructurings”) to manage costs and as a consequence of our decision to focus our proprietary resources and development efforts on the development and commercialization of cabozantinib. The aggregate reduction in headcount from the Restructurings was 429 employees. Charges and credits related to the Restructurings were recorded in periods other than those in which the Restructurings were implemented as a result of sublease activities for certain of our buildings in South San Francisco, California, changes in assumptions regarding anticipated sublease activities, the effect of the passage of time on our discounted cash flow computations, previously planned employee terminations, and sales of excess equipment and other assets.
	We have recorded aggregate restructuring charges of $53.7 million in connection with the Restructurings, of which $29.7 million related to facility charges, $21.7 million related to termination benefits, $2.2 million related to the impairment of excess equipment and other assets, and an additional minor amount related to legal and other fees.
	For the six months ended June 30, 2014 and 2013, we recorded restructuring charges of $0.4 million and $0.7 million, respectively. The charges for both periods presented were related to the effect of the passage of time on our discounted cash flow computations for the exit, in prior periods, of certain of our South San Francisco buildings. During the six months ended June 30, 2014, those charges were partially offset by $0.1 million in recoveries recorded in connection with the sale of excess equipment and other assets.
	The total outstanding restructuring liability related to the Restructurings is included in the current and long-term portion of restructuring on the accompanying Consolidated Balance Sheets. The components and changes of these liabilities during the annual periods from inception of the restructuring activities through the year ended December 31, 2013 and during the six months ended June 30, 2014 are summarized in the following table (in thousands):
		Facility			Other			Total
		Charges
	Restructuring liability as of December 31, 2012	$	19,202		$	20		$	19,222
	Restructuring charge	662			569			1,231
	Cash payments	(6,331		)	(434		)	(6,765		)
	Adjustments or non-cash credits including stock compensation expense	(73		)	(238		)	(311		)
	Proceeds from sale of assets	—			95			95
	Restructuring liability as of December 31, 2013	13,460			12			13,472
	Restructuring charge (credit)	490			(113		)	377
	Cash payments	(3,496		)	(6		)	(3,502		)
	Adjustments or non-cash credits	9			(86		)	(77		)
	Proceeds from sale of assets	—			199			199
	Restructuring liability as of June 30, 2014	$	10,463		$	6		$	10,469
	We expect to pay accrued facility charges of $10.5 million, net of cash received from our subtenants, through the end of our lease terms of the buildings, the last of which ends in 2017. With respect to our Restructurings, we expect to incur additional restructuring charges of approximately $1.1 million which relates to the effect of the passage of time on our discounted cash flow computations for the exit, in prior periods, of certain of our South San Francisco buildings. These charges will be recorded through the end of the building lease terms, the last of which ends in 2017.
	The Restructurings have resulted in aggregate cash expenditures of $38.7 million, net of $12.2 million in cash received from subtenants and $2.9 million in cash received in connection with the sale of excess equipment and other assets. Net cash expenditures for the Restructurings were $3.3 million and $4.0 million during the six months ended June 30, 2014 and 2013, respectively.
	The restructuring charges that we expect to incur in connection with the Restructurings are subject to a number of assumptions, and actual results may materially differ. We may also incur other material charges not currently contemplated due to events that may occur as a result of, or associated with, the Restructurings.

Cash_and_Investments

Cash and Investments	6 Months Ended
	Jun. 30, 2014
Investments, Debt and Equity Securities [Abstract]	'
Cash and Investments	'
	CASH AND INVESTMENTS
	The following table summarizes cash and cash equivalents, investments, and restricted cash and investments by balance sheet line item as of June 30, 2014 and December 31, 2013 (in thousands):
		June 30, 2014
		Amortized		Gross		Gross			Fair Value
		Cost		Unrealized		Unrealized
				Gains		Losses
	Cash and cash equivalents	$	147,339	$	2	$	(1	)	$	147,340
	Short-term investments	86,046		140		(9		)	86,177
	Short-term restricted cash and investments	12,143		71		—			12,214
	Long-term investments	95,489		47		(23		)	95,513
	Long-term restricted cash and investments	10,726		55		—			10,781
	Total cash and investments	$	351,743	$	315	$	(33	)	$	352,025
		December 31, 2013
		Amortized		Gross		Gross			Fair Value
		Cost		Unrealized		Unrealized
				Gains		Losses
	Cash and cash equivalents	$	103,978	$	—	$	—		$	103,978
	Short-term investments	138,403		94		(22		)	138,475
	Short-term restricted cash and investments	12,173		40		—			12,213
	Long-term investments	144,226		106		(33		)	144,299
	Long-term restricted cash and investments	16,837		60		—			16,897
	Total cash and investments	$	415,617	$	300	$	(55	)	$	415,862
	Under our loan and security agreement with Silicon Valley Bank, we are required to maintain compensating balances on deposit in one or more investment accounts with Silicon Valley Bank or one of its affiliates. The total collateral balances as of June 30, 2014 and December 31, 2013 were $82.8 million and $83.7 million, respectively, and are reflected on the accompanying Consolidated Balance Sheets in short- and long-term investments. See “Note 8 - Debt” to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2013, for more information regarding the collateral balance requirements under our Silicon Valley Bank loan and security agreement.
	All of our cash equivalents and investments are classified as available-for-sale. The following table summarizes our cash equivalents and investments by security type as of June 30, 2014 and December 31, 2013. The amounts presented exclude cash, but include investments classified as cash equivalents (in thousands):
		June 30, 2014
		Amortized		Gross		Gross			Fair Value
		Cost		Unrealized		Unrealized
				Gains		Losses
	Money market funds	$	49,184	$	—	$	—		$	49,184
	Commercial paper	97,856		—		—			97,856
	Corporate bonds	150,828		178		(32		)	150,974
	U.S. Treasury and government sponsored enterprises	26,186		126		(1		)	26,311
	Municipal bonds	24,246		11		—			24,257
	Total investments	$	348,300	$	315	$	(33	)	$	348,582
		December 31, 2013
		Amortized		Gross		Gross			Fair Value
		Cost		Unrealized		Unrealized
				Gains		Losses
	Money market funds	$	24,813	$	—	$	—		$	24,813
	Commercial paper	94,682		—		—			94,682
	Corporate bonds	239,937		190		(55		)	240,072
	U.S. Treasury and government sponsored enterprises	44,284		102		—			44,386
	Municipal bonds	6,005		8					6,013
	Total investments	$	409,721	$	300	$	(55	)	$	409,966
	There were no realized gains or losses on the sales of investments during the six months ended June 30, 2014 and 2013.
	All of our investments are subject to a quarterly impairment review. During the six months ended June 30, 2014 and 2013, we did not record any other-than-temporary impairment charges on our available-for-sale securities. As of June 30, 2014, there were 25 investments in an unrealized loss position with an aggregate fair value $50.1 million. The investments in an unrealized loss position are primarily corporate bonds. All of our investments in an unrealized loss position have been so for less than one year and the unrealized losses were not attributed to credit risk, but rather associated with the changes in interest rates. Based on the scheduled maturities of our investments, we concluded that the unrealized losses in our investment securities are not other-than-temporary, as it is more likely than not that we will hold these investments for a period of time sufficient for a recovery of our cost basis.
	The following summarizes the fair value of securities classified as available-for-sale by contractual maturity as of June 30, 2014 (in thousands):
		Mature within One Year		After One Year through Two Years		Fair Value
	Money market funds	$	49,184	$	—	$	49,184
	Commercial paper	97,856		—		97,856
	Corporate bonds	111,449		39,525		150,974
	U.S. Treasury and government sponsored enterprises	20,215		6,096		26,311
	Municipal bonds	24,257		—		24,257
	Total investments	$	302,961	$	45,621	$	348,582
	Cash is excluded from the table above. The classification of certain compensating balances and restricted investments are dependent upon the term of the underlying restriction on the asset and not the maturity date of the investment. Therefore, certain long-term investments and long-term restricted cash and investments have contractual maturities within one year.

Inventory

Inventory	6 Months Ended
	Jun. 30, 2014
Inventory Disclosure [Abstract]	'
Inventory	'
	INVENTORY
	Inventory consists of the following (in thousands):
		June 30,		December 31,
		2014		2013
	Raw materials	$	643	$	529
	Work in process	1,871		2,280
	Finished goods	512		81
	Total	$	3,026	$	2,890
	We received regulatory approval in the United States for our first product, COMETRIQ, on November 29, 2012. A significant portion of the manufacturing costs for our inventory were incurred prior to regulatory approval of COMETRIQ for the treatment of progressive, metastatic MTC and, therefore, were expensed as research and development costs when those costs were incurred, rather than capitalized as inventory.

Debt

Debt	6 Months Ended
	Jun. 30, 2014
Debt Disclosure [Abstract]	'
Debt	'
	DEBT
	The amortized carrying amount of our debt consists of the following (in thousands):
		June 30,			December 31,
		2014			2013
	Convertible Senior Subordinated Notes due 2019	$	173,635		$	165,296
	Secured Convertible Notes due 2015	94,207			99,851
	Silicon Valley Bank term loan	80,000			80,000
	Silicon Valley Bank line of credit	1,132			2,090
	Total debt	348,974			347,237
	Less: current portion	(95,284		)	(11,762		)
	Long-term debt	$	253,690		$	335,475
	See “Note 8 - Debt” to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2013, for additional information on the terms of our debt, including a description of the conversion features of the of 4.25% Convertible Senior Subordinated Notes due 2019 (the “2019 Notes”) and our Secured Convertible Notes due June 2015 (the “Deerfield Notes”).
	Convertible Senior Subordinated Notes due 2019
	In August 2012, we issued and sold $287.5 million aggregate principal amount of the 2019 Notes. As of June 30, 2014, the entire principal balance remains outstanding. The following is a summary of the liability component of the 2019 Notes (in thousands):
		June 30,			December 31,
		2014			2013
	Net carrying amount of the liability component	$	173,635		$	165,296
	Unamortized discount of the liability component	113,865			122,204
	Face amount of the 2019 Notes	$	287,500		$	287,500
	The debt discount and debt issuance costs will be amortized as interest expense through August 2019. The following is a summary of interest expense for the 2019 Notes (in thousands):
		Three Months Ended June 30,						Six Months Ended June 30,
		2014			2013			2014		2013
	Stated coupon interest	$	3,054		$	3,054		$	6,143	$	6,109
	Amortization of debt discount and debt issuance costs	4,397			4,001			8,692		7,910
	Total interest expense	$	7,451		$	7,055		$	14,835	$	14,019
	The balance of unamortized fees and costs was $3.6 million and $4.0 million as of June 30, 2014 and December 31, 2013, respectively, which is included in Other assets on the accompanying Consolidated Balance Sheets.
	Secured Convertible Notes due June 2015
	In June 2010, we entered into a note purchase agreement with entities affiliated with Deerfield Management Company, L.P. (“Deerfield”), pursuant to which, on July 1, 2010, we sold to Deerfield an aggregate of $124.0 million in principal amount of the Deerfield Notes. As of June 30, 2014 and December 31, 2013, the remaining outstanding principal balance on the Deerfield Notes was $104.0 million and $114.0 million, respectively, which, subject to certain limitations, is payable in cash or in stock at our discretion. The following is a summary of interest expense for the Deerfield Notes (in thousands):
		Three Months Ended June 30,						Six Months Ended June 30,
		2014			2013			2014		2013
	Stated coupon interest	$	1,495		$	1,496		$	2,975	$	2,975
	Amortization of debt discount and debt issuance costs	2,931			2,478			5,626		4,883
	Total interest expense	$	4,426		$	3,974		$	8,601	$	7,858
	The balance of unamortized fees and costs was $2.9 million and $1.4 million as of June 30, 2014 and December 31, 2013, respectively, which is included in Other assets on the accompanying Consolidated Balance Sheets.
	On January 22, 2014, the note purchase agreement was amended to provide us with an option to extend the maturity date of our indebtedness under the note purchase agreement to July 1, 2018 (the “Extension Option”). Under the terms of the Extension Option, which expires on March 31, 2015, we have the right to require Deerfield Partners, L.P. and Deerfield International Master Fund, L.P. (the “New Deerfield Purchasers”) to acquire $100 million principal amount of the Deerfield Notes and extend the maturity date to July 1, 2018. If we exercise the Extension Option, the Deerfield Notes would bear interest on and after July 2, 2015 at the rate of 7.5% per annum to be paid in cash, quarterly in arrears, and 7.5% per annum to be paid in kind, quarterly in arrears, for a total interest rate of 15% per annum. We are under no obligation to exercise the Extension Option.
	In connection with the amendment to the note purchase agreement, on January 22, 2014 we issued to the New Deerfield Purchasers two-year warrants (the “2014 Deerfield Warrants”) to purchase an aggregate of 1,000,000 shares of our common stock at an exercise price of $9.70 per share, which exercise price is subject to change in the event we exercise the Extension Option. See “Note 6 - Common Stock and Warrants” for further information on those warrants.
	We determined that the amendment resulted in the Deerfield Notes being modified. In connection with the amendment, we recorded a $2.8 million deferred commitment fee upon the issuance of the 2014 Deerfield Warrants. See “Note 6 - Common Stock and Warrants” for further information on those warrants. The deferred commitment fee is included in Other assets and will be amortized into interest expense as a yield adjustment through the current maturity date of the Deerfield Notes, July 1, 2015. Third-party expenses, comprised primarily of legal and accounting fees, were expensed as of the date of the amendment.

Common_Stock_And_Warrants

Common Stock And Warrants	6 Months Ended
	Jun. 30, 2014
Warrants and Rights Note Disclosure [Abstract]	'
Common Stock And Warrants	'
	COMMON STOCK AND WARRANTS
	Sale of Shares of Common Stock
	In January 2014 we completed a registered underwritten public offering of 10.0 million shares of our common stock at a price of $8.00 per share pursuant to a shelf registration statement previously filed with the SEC, which the SEC declared effective on June 8, 2012. We received $75.6 million in net proceeds from the offering after deducting the underwriting discount and related offering expenses.
	Warrants
	On January 22, 2014, in connection with the amendment to the note purchase agreement to provide us with the Extension Option, we issued to the New Deerfield Purchasers the 2014 Deerfield Warrants to purchase an aggregate of 1,000,000 shares of our common stock at an exercise price of $9.70 per share. If we exercise the Extension Option, the term of the 2014 Deerfield Warrants will be extended by two years and the exercise price will be reset to the lower of (i) the existing exercise price and (ii) 120% of the volume weighted average price of our common stock for the ten trading days immediately following the date of such extension election. Due to the potential increase in term and decrease of the exercise price, the 2014 Deerfield Warrants were recorded as a liability which is included in Other long-term liabilities. The 2014 Deerfield Warrants are recorded at fair value, on a recurring basis, which was $0.9 million and $2.8 million as of June 30, 2014 and January 22, 2014, respectively. We recorded an unrealized gain on the warrants of $0.1 million and $1.9 million during the three and six months ended June 30, 2014, respectively, which is included in Interest income and other, net. See “Note 7 - Fair Value Measurements” for more information on the valuation of these warrants.
	At June 30, 2014, the following warrants to purchase common stock were outstanding and exercisable:
	Date Issued	Exercise		Expiration Date	Number
		Price per Share			of Shares
	January 22, 2014	$	9.7	January 22, 2016	1,000,000
	The warrants are participating securities. The warrant holders do not have a contractual obligation to share in our losses.

Fair_Value_Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2014
Fair Value Disclosures [Abstract]	'
Fair Value Measurements	'
	FAIR VALUE MEASUREMENTS
	The following table sets forth the fair value of our financial assets and liabilities that were measured and recorded on a recurring basis as of June 30, 2014 and December 31, 2013. We did not have any financial liabilities that were measured and recorded on a recurring basis or Level 3 investments as of December 31, 2013. The amounts presented exclude cash, but include investments classified as cash equivalents (in thousands):
		June 30, 2014
		Level 1			Level 2			Level 3		Total
	Financial assets:
	Money market funds	$	49,184		$	—		$	—	$	49,184
	Commercial paper	—			97,856			—		97,856
	Corporate bonds	—			150,974			—		150,974
	U.S. Treasury and government sponsored enterprises	—			26,311			—		26,311
	Municipal bonds	—			24,257			—		24,257
	Total financial assets	$	49,184		$	299,398		$	—	$	348,582
	Financial liabilities:
	Warrants	$	—		$	—		$	908	$	908
	Total financial liabilities	$	—		$	—		$	908	$	908
		December 31, 2013
		Level 1			Level 2			Total
	Money market funds	$	24,813		$	—		$	24,813
	Commercial paper	—			94,682			94,682
	Corporate bonds	—			240,072			240,072
	U.S. Treasury and government sponsored enterprises	—			44,386			44,386
	Municipal bonds	—			6,013			6,013
	Total financial assets	$	24,813		$	385,153		$	409,966
	There were no transfers between any of the fair value hierarchies, as determined at the end of each reporting period.
	The estimated fair values of our financial instruments that are carried at amortized cost for which it is practicable to determine a fair value were as follows (in thousands):
		June 30, 2014						December 31, 2013
		Carrying			Fair Value			Carrying		Fair Value
		Amount						Amount
	2019 Notes	$	173,635		$	245,640		$	165,296	$	339,883
	Silicon Valley Bank term loan	$	80,000		$	79,954		$	80,000	$	79,946
	Silicon Valley Bank line of credit	$	1,132		$	1,132		$	2,090	$	2,090
	We believe it is not practicable to determine the fair value of the Deerfield Notes due to the unique structure of the instrument that was financed by entities affiliated with Deerfield.
	The carrying amounts of cash, trade and other receivables, accounts payable and accrued clinical trial liabilities approximate their fair values and are excluded from the tables above.
	The following methods and assumptions were used to estimate the fair value of each class of financial instrument for which it is practicable to estimate a value:
	•	When available, we value investments based on quoted prices for those financial instruments, which is a Level 1 input. Our remaining investments are valued using third-party pricing sources, which use observable market prices, interest rates and yield curves observable at commonly quoted intervals of similar assets as observable inputs for pricing, which is a Level 2 input.
	•	The 2019 Notes are valued using a third-party pricing model that is based in part on average trading prices, which is a Level 2 input. The 2019 Notes are not marked-to-market and are shown at their initial fair value less the unamortized discount; the portion of the value allocated to the conversion option is included in Stockholders’ equity on the accompanying Consolidated Balance Sheets.
	•	We estimate the fair value of our other debt instruments, where possible, using the net present value of the payments discounted at an interest rate that is consistent with money-market rates that would have been earned on our non-interest-bearing compensating balances, which is a Level 2 input.
	•	The 2014 Deerfield Warrants are valued using a Monte Carlo simulation model. The expected life is based on the contractual terms of the 2014 Deerfield Warrants, and in certain simulations, assumes the two year extension that would result from our exercise of the Extension Option. We consider implied volatility as well as our historical volatility in developing our estimate of expected volatility. The fair value of the 2014 Deerfield Warrants were estimated using the following assumptions, which, except for risk-free interest rate, are Level 3 inputs (dollars in thousands):
					22-Jan-14
		June 30, 2014			(issuance date)
	Fair value of warrants	$	908		$	2,762
	Risk-free interest rate	0.98		%	0.95		%
	Dividend yield	—		%	—		%
	Volatility	81		%	57		%
	Average expected life	2.8 years			3.2 years

StockBased_Compensation

Stock-Based Compensation	6 Months Ended
	Jun. 30, 2014
Share-based Compensation [Abstract]	'
Stock-Based Compensation	'
	STOCK-BASED COMPENSATION
	We recorded and allocated employee stock-based compensation expenses for our equity incentive plans and our 2000 Employee Stock Purchase Plan (“ESPP”) as follows (in thousands):
		Three Months Ended June 30,								Six Months Ended June 30,
		2014				2013				2014			2013
	Research and development expense	$	1,471			$	1,553			$	3,036		$	2,960
	Selling, general and administrative expense	2,511				1,370				4,704			2,638
	Total employee stock-based compensation expense	$	3,982			$	2,923			$	7,740		$	5,598
	We use the Black-Scholes option pricing model to value our stock options. The expected life computation is based on historical exercise patterns and post-vesting termination behavior. We considered implied volatility as well as our historical volatility in developing our estimate of expected volatility. The fair value of employee stock option awards and ESPP purchases was estimated using the following assumptions and weighted average fair values:
		Stock Options
		Three Months Ended June 30,								Six Months Ended June 30,
		2014				2013				2014			2013
	Weighted average grant-date fair value	$	2.33			$	2.56			$	3.65		$	2.52
	Risk-free interest rate	1.75		%		0.98		%		1.66		%	0.92		%
	Dividend yield	—		%		—		%		—		%	—		%
	Volatility	80		%		62		%		81		%	62		%
	Expected life	5.8 years				5.6 years				5.6 years			5.5 years
		Employee Stock Purchase Plan
		Three Months Ended June 30,								Six Months Ended June 30,
		2014				2013				2014			2013
	Weighted average grant-date fair value	$	1.32			$	1.65			$	1.44		$	1.63
	Risk-free interest rate	0.06		%		0.12		%		0.07		%	0.13		%
	Dividend yield	—		%		—		%		—		%	—		%
	Volatility	67		%		67		%		64		%	67		%
	Expected life	6 months				6 months				6 months			6 months
	Of the stock options outstanding as of June 30, 2014, 3,640,752 were granted subject to performance objectives tied to the achievement of goals set by the Compensation Committee of our Board of Directors and will vest in full or part based on achievement of such goals. As of June 30, 2014, we expect that achievement of some of those performance objectives is probable and have, therefore, recorded stock-based compensation expense in connection with such awards. We have not included any stock-based compensation expense for stock options with performance objectives for which the achievement of the performance goals is not considered probable; the grant date fair value of such awards outstanding was $6.7 million.
	A summary of all stock option activity for the six months ended June 30, 2014 is presented below (dollars in thousands, except per share amounts):
		Shares			Weighted				Weighted		Aggregate
					Average				Average		Intrinsic
					Exercise Price				Remaining Contractual		Value
									Term
	Options outstanding at December 31, 2013	23,983,275			$	6.48
	Granted	1,120,530			$	5.4
	Exercised	(19,090	)		$	6.28
	Forfeited	(166,405	)		$	5.52
	Expired	(423,467	)		$	7.85
	Options outstanding at June 30, 2014	24,494,843			$	6.41			4.30 years		$	37
	Exercisable at June 30, 2014	14,527,591			$	7.05			3.21 years		$	2
	As of June 30, 2014, $16.6 million of total unrecognized compensation expense related to employee stock options was expected to be recognized over a weighted-average period of 2.30 years.
	A summary of all restricted stock unit (“RSU”) activity for the six months ended June 30, 2014 is presented below (dollars in thousands, except per share amounts):
		Shares			Weighted				Weighted		Aggregate
					Average				Average		Intrinsic
					Grant Date				Remaining		Value
					Fair Value				Contractual
									Term
	Awards outstanding at December 31, 2013	1,810,521			$	5.56
	Awarded	61,842			$	5.19
	Released	(101,600	)		$	6.78
	Forfeited	(62,540	)		$	5.52
	Awards outstanding at June 30, 2014	1,708,223			$	5.48			2.96 years		$	5,928
	As of June 30, 2014, $6.2 million of total unrecognized compensation expense related to employee RSUs was expected to be recognized over a weighted-average period of 2.96 years.

Net_Loss_Per_Share

Net Loss Per Share	6 Months Ended
	Jun. 30, 2014
Earnings Per Share [Abstract]	'
Net Loss Per Share	'
	NET LOSS PER SHARE
	The following table sets forth a reconciliation of basic and diluted net loss per share (in thousands, except per share amounts):
		Three Months Ended June 30,							Six Months Ended June 30,
		2014				2013			2014			2013
	Numerator:
	Net loss	$	(73,410	)		$	(62,161	)	$	(148,029	)	$	(106,890	)
	Denominator:
	Shares used in computing basic and diluted net loss per share	194,929				183,981			193,323			183,861
	Net loss per share, basic and diluted	$	(0.38	)		$	(0.34	)	$	(0.77	)	$	(0.58	)
	The following table sets forth outstanding potential shares of common stock that are not included in the computation of diluted net loss per share because, to do so would be anti-dilutive (in thousands):
		June 30
		2014			2013
	Convertible debt	54,123			54,123
	Outstanding stock options, unvested RSUs and ESPP contributions	26,308			18,147
	Warrants	1,000			1,441
	Total potentially dilutive shares	81,431			73,711

Concentrations_of_Credit_Risk

Concentrations of Credit Risk	6 Months Ended
	Jun. 30, 2014
Risks and Uncertainties [Abstract]	'
Concentrations of Credit Risk	'
	CONCENTRATIONS OF CREDIT RISK
	Financial instruments that potentially subject us to concentrations of credit risk are primarily trade and other receivables and investments. Investments consist of money market funds, taxable commercial paper, corporate bonds with high credit quality, U.S. Treasury and government sponsored enterprises, and municipal bonds. All investments are maintained with financial institutions that management believes are creditworthy.
	Trade and other receivables are unsecured and are concentrated in the pharmaceutical and biotechnology industries. Accordingly, we may be exposed to credit risk generally associated with pharmaceutical and biotechnology companies. We have incurred no bad debt expense since inception. As of June 30, 2014, 78% of our trade and other receivables are with the specialty pharmacy that sells COMETRIQ in the United States and 12% are with our European distribution partner. Both of these customers pay promptly and within their respective payment terms. All of our long-lived assets are located in the United States.
	We have operations primarily in the United States, while some of our collaboration partners have headquarters outside of the United States and certain of our clinical trials for cabozantinib are conducted outside of the United States. During the second quarter of 2013, we initiated a Named Patient Use (“NPU”) program through our distribution partner, Swedish Orphan Biovitrum (“Sobi”), to support the distribution and commercialization of COMETRIQ for metastatic MTC primarily in the European Union and potentially other countries. In March 2014, the European Commission approved cabozantinib for the treatment of adult patients with progressive, unresectable locally advanced or metastatic MTC, also under the brand name COMETRIQ. In June 2014, we began selling COMETRIQ to Sobi in preparation for commercial sales in certain countries in the European Union. The following table shows the percentage of revenues earned in the United States. The remainder of our revenues were earned in the European Union.
		Three Months Ended June 30,				Six Months Ended June 30,
		2014		2013		2014		2013
	Percentage of revenues earned in the United States	93	%	98	%	96	%	99	%
	The following table sets forth the percentage of revenues recognized under our collaboration agreements and product sales to the specialty pharmacy that represent 10% or more of total revenues during the three and six months ended June 30, 2014 and 2013:
		Three Months Ended June 30,				Six Months Ended June 30,
		2014		2013		2014		2013
	Collaboration agreement:
	Bristol-Myers Squibb	—	%	66	%	—	%	73	%
	Product sales:
	Diplomat Specialty Pharmacy	93	%	32	%	96	%	26	%

Organization_and_Summary_of_Si1

Organization and Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Organization	'
	Organization
	Exelixis, Inc. (“Exelixis,” “we,” “our” or “us”) is a biopharmaceutical company committed to developing small molecule therapies for the treatment of cancer. Our two most advanced assets are cabozantinib, our wholly-owned inhibitor of multiple receptor tyrosine kinases, and cobimetinib (GDC-0973/XL518), a potent, highly selective inhibitor of MEK, which we out-licensed to Genentech (a member of the Roche Group) (“Genentech”). We are evaluating cabozantinib in a broad development program, including five ongoing phase 3 pivotal trials. We currently expect top-line results in 2014 from our two phase 3 pivotal trials of cabozantinib in metastatic castration-resistant prostate cancer, and from the overall survival analysis of our phase 3 EXAM pivotal trial of cabozantinib in progressive metastatic medullary thyroid cancer (“MTC”). Genentech is evaluating cobimetinib in a broad development program. On July 14, 2014, we reported positive top-line results from Genentech’s coBRIM study, a phase 3 pivotal trial evaluating cobimetinib in combination with vemurafenib in previously untreated patients with unresectable locally advanced or metastatic melanoma harboring a BRAFV600 mutation.
	We are focusing our development and commercialization efforts primarily on cabozantinib. Cabozantinib was approved by the U.S. Food and Drug Administration (“FDA”), on November 29, 2012, for the treatment of progressive, metastatic MTC, in the United States under the brand name COMETRIQ(R). COMETRIQ became commercially available in the United States in late January 2013. In March 2014, the European Commission approved cabozantinib for the treatment of adult patients with progressive, unresectable locally advanced or metastatic MTC, also under the brand name COMETRIQ. The European Commission granted conditional marketing authorization following a positive opinion from the European Committee for Medicinal Products for Human Use (“CHMP”), issued in December 2013.
Basis of Consolidation	'
	Basis of Consolidation
	The consolidated financial statements include the accounts of Exelixis and those of our wholly-owned subsidiaries. These entities’ functional currency is the U.S. dollar. All intercompany balances and transactions have been eliminated.
Basis of Presentation	'
	Basis of Presentation
	The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. In our opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of the results of operations and cash flows for the period presented have been included.
	Exelixis adopted a 52- or 53-week fiscal year that generally ends on the Friday closest to December 31st. Fiscal year 2013, a 52-week year, ended on December 27, 2013, and fiscal year 2014, a 53-week year, will end on January 2, 2015. For convenience, references in this report as of and for the fiscal periods ended June 27, 2014 and June 28, 2013, and as of the fiscal year ended December 27, 2013, are indicated as ended June 30, 2014, June 30, 2013, and December 31, 2013, respectively.
	Operating results for the six months ended June 30, 2014 are not necessarily indicative of the results that may be expected for the fiscal year ending January 2, 2015 or for any future period. These financial statements and notes should be read in conjunction with the consolidated financial statements and notes thereto for the year ended December 31, 2013, included in our Annual Report on Form 10-K filed with the SEC on February 20, 2014.
Fiscal Period, Policy	'
	Exelixis adopted a 52- or 53-week fiscal year that generally ends on the Friday closest to December 31st. Fiscal year 2013, a 52-week year, ended on December 27, 2013, and fiscal year 2014, a 53-week year, will end on January 2, 2015. For convenience, references in this report as of and for the fiscal periods ended June 27, 2014 and June 28, 2013, and as of the fiscal year ended December 27, 2013, are indicated as ended June 30, 2014, June 30, 2013, and December 31, 2013, respectively.
Segment Information	'
	Segment Information
	We operate as a single reportable segment.
Use of Estimates	'
	Use of Estimates
	The preparation of our consolidated financial statements is in conformity with accounting principles generally accepted in the United States which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. On an ongoing basis, management evaluates its estimates including, but not limited to, those related to inventory, revenue recognition, valuation of long-lived assets, certain accrued liabilities including clinical trial accruals and restructuring liability, valuation of warrants, share-based compensation and the valuation of the debt and equity components of our convertible debt at issuance. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.
Revenue Recognition	'
	Revenue Recognition
	We recognize revenue from the sale of COMETRIQ and from license fees and milestones earned on research and collaboration arrangements. See “Note 1 - Organization and Summary of Significant Accounting Policies” to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2013 for a description of our policies for revenue recognition on research and collaboration agreements. We did not enter into any new collaboration agreements during the six months ended June 30, 2014. See “Note 2 - Research and Collaboration Agreements” to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2013 for a description of our existing collaboration agreements.
	Net Product Revenues
	We recognize revenue when it is both realized or realizable and earned, meaning persuasive evidence of an arrangement exists, delivery has occurred, title has transferred, the price is fixed or determinable, there are no remaining customer acceptance requirements, and collectability of the resulting receivable is reasonably assured. For product sales in the United States, this generally occurs upon shipment of the product to the patient by our distributor. For product sales in Europe, this occurs when our European distribution partner has accepted the product.
	We sell our product, COMETRIQ, in the United States to a specialty pharmacy that benefits from customer incentives and has a right of return. We have a limited sales history and cannot reliably estimate expected returns of the product nor the discounts and rebates due to payors at the time of shipment to the specialty pharmacy. Accordingly, upon shipment to the specialty pharmacy, we record deferred revenue on our Consolidated Balance Sheets. We recognize revenue when the specialty pharmacy provides the product to a patient based on the fulfillment of a prescription. We record revenue using an analysis of prescription data from our specialty pharmacy to ascertain the date of shipment and the payor mix. This approach is frequently referred to as the “sell-through” revenue recognition model. Once the prescription has been provided to the patient, it is not subject to return unless the product is damaged.
	We record revenue at the time our European distribution partner has accepted the product, a method also known as the “sell-in” revenue recognition model.
	Product Sales Discounts and Allowances
	We calculate gross product revenues based on the price that we charge our United States specialty pharmacy and our European distribution partner. We estimate our domestic net product revenues by deducting from our gross product revenues (a) trade allowances, such as discounts for prompt payment, (b) estimated government rebates and chargebacks, and (c) estimated costs of patient assistance programs. We initially record estimates for these deductions at the time we recognize the gross revenue. We update our estimates on a recurring basis as new information becomes available. Our European distribution partner is entitled to receive a project management fee based upon the achievement of a pre-specified revenue goal which, when deemed probable, is ratably accrued as a reduction to gross revenue. See “Note 1 - Organization and Summary of Significant Accounting Policies” to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2013 for a further description of our discounts and allowances.
Cost of Goods Sold	'
	Cost of Goods Sold
	Cost of goods sold is related to our product revenues and consisted primarily of a 3% royalty and indirect labor costs, and to a lesser extent, the cost of manufacturing and other third party logistics costs of our product. A significant portion of the manufacturing costs for product sales were incurred prior to regulatory approval of COMETRIQ for the treatment of progressive, metastatic MTC and, therefore, were expensed as research and development costs when those costs were incurred, rather than capitalized as inventory.
	In accordance with our product development and commercialization agreement with GlaxoSmithKline, we are required to pay GlaxoSmithKline a 3% royalty on the Net Sales of any product incorporating cabozantinib, including COMETRIQ. Net Sales is defined in the product development and commercialization agreement generally as the gross invoiced sales price less customer credits, rebates, chargebacks, shipping costs, customs duties, and sales tax and other similar tax payments we are required to make.
Recently Issued Accounting Pronouncements	'
	Recently Issued Accounting Pronouncements
	In May 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2014-09, Revenue from Contracts with Customers ("ASU 2014-09"). ASU 2014-09 supersedes the revenue recognition requirements of FASB Accounting Standards Codification ("ASC") Topic 605, Revenue Recognition and most industry-specific guidance throughout the Accounting Standards Codification, resulting in the creation of FASB ASC Topic 606, Revenue from Contracts with Customers. ASU 2014-09 requires entities to recognize revenue in a way that depicts the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. Adoption will be permitted using either a retrospective or modified retrospective approach, and is effective for fiscal years, and interim periods within those years, beginning after December 15, 2016. Early adoption is not permitted. We are currently evaluating the impact of adopting this ASU, inclusive of available transitional methods on our consolidated financial statements and related disclosures.

Restructurings_Tables

Restructurings (Tables)	6 Months Ended
	Jun. 30, 2014
Restructuring Charges [Abstract]	'
Summary Of Components Of Restructuring Liability	'
	The components and changes of these liabilities during the annual periods from inception of the restructuring activities through the year ended December 31, 2013 and during the six months ended June 30, 2014 are summarized in the following table (in thousands):
		Facility			Other			Total
		Charges
	Restructuring liability as of December 31, 2012	$	19,202		$	20		$	19,222
	Restructuring charge	662			569			1,231
	Cash payments	(6,331		)	(434		)	(6,765		)
	Adjustments or non-cash credits including stock compensation expense	(73		)	(238		)	(311		)
	Proceeds from sale of assets	—			95			95
	Restructuring liability as of December 31, 2013	13,460			12			13,472
	Restructuring charge (credit)	490			(113		)	377
	Cash payments	(3,496		)	(6		)	(3,502		)
	Adjustments or non-cash credits	9			(86		)	(77		)
	Proceeds from sale of assets	—			199			199
	Restructuring liability as of June 30, 2014	$	10,463		$	6		$	10,469

Cash_and_Investments_Cash_and_

Cash and Investments Cash and Investments (Tables)	6 Months Ended
	Jun. 30, 2014
Investments, Debt and Equity Securities [Abstract]	'
Schedule of Available-for-Sale Securities	'
	The following table summarizes cash and cash equivalents, investments, and restricted cash and investments by balance sheet line item as of June 30, 2014 and December 31, 2013 (in thousands):
		June 30, 2014
		Amortized		Gross		Gross			Fair Value
		Cost		Unrealized		Unrealized
				Gains		Losses
	Cash and cash equivalents	$	147,339	$	2	$	(1	)	$	147,340
	Short-term investments	86,046		140		(9		)	86,177
	Short-term restricted cash and investments	12,143		71		—			12,214
	Long-term investments	95,489		47		(23		)	95,513
	Long-term restricted cash and investments	10,726		55		—			10,781
	Total cash and investments	$	351,743	$	315	$	(33	)	$	352,025
		December 31, 2013
		Amortized		Gross		Gross			Fair Value
		Cost		Unrealized		Unrealized
				Gains		Losses
	Cash and cash equivalents	$	103,978	$	—	$	—		$	103,978
	Short-term investments	138,403		94		(22		)	138,475
	Short-term restricted cash and investments	12,173		40		—			12,213
	Long-term investments	144,226		106		(33		)	144,299
	Long-term restricted cash and investments	16,837		60		—			16,897
	Total cash and investments	$	415,617	$	300	$	(55	)	$	415,862
Summary of Cash and Investments by Security Type	'
	The amounts presented exclude cash, but include investments classified as cash equivalents (in thousands):
		June 30, 2014
		Amortized		Gross		Gross			Fair Value
		Cost		Unrealized		Unrealized
				Gains		Losses
	Money market funds	$	49,184	$	—	$	—		$	49,184
	Commercial paper	97,856		—		—			97,856
	Corporate bonds	150,828		178		(32		)	150,974
	U.S. Treasury and government sponsored enterprises	26,186		126		(1		)	26,311
	Municipal bonds	24,246		11		—			24,257
	Total investments	$	348,300	$	315	$	(33	)	$	348,582
		December 31, 2013
		Amortized		Gross		Gross			Fair Value
		Cost		Unrealized		Unrealized
				Gains		Losses
	Money market funds	$	24,813	$	—	$	—		$	24,813
	Commercial paper	94,682		—		—			94,682
	Corporate bonds	239,937		190		(55		)	240,072
	U.S. Treasury and government sponsored enterprises	44,284		102		—			44,386
	Municipal bonds	6,005		8					6,013
	Total investments	$	409,721	$	300	$	(55	)	$	409,966
Summary of Available-for-Sale Securities by Contractual Maturity	'
	The following summarizes the fair value of securities classified as available-for-sale by contractual maturity as of June 30, 2014 (in thousands):
		Mature within One Year		After One Year through Two Years		Fair Value
	Money market funds	$	49,184	$	—	$	49,184
	Commercial paper	97,856		—		97,856
	Corporate bonds	111,449		39,525		150,974
	U.S. Treasury and government sponsored enterprises	20,215		6,096		26,311
	Municipal bonds	24,257		—		24,257
	Total investments	$	302,961	$	45,621	$	348,582

Inventory_Tables

Inventory (Tables)	6 Months Ended
	Jun. 30, 2014
Inventory Disclosure [Abstract]	'
Schedule of Inventory	'
	Inventory consists of the following (in thousands):
		June 30,		December 31,
		2014		2013
	Raw materials	$	643	$	529
	Work in process	1,871		2,280
	Finished goods	512		81
	Total	$	3,026	$	2,890

Debt_Tables

Debt (Tables)	6 Months Ended
	Jun. 30, 2014
Debt Disclosure [Abstract]	'
Schedule Of Debt	'
	The amortized carrying amount of our debt consists of the following (in thousands):
		June 30,			December 31,
		2014			2013
	Convertible Senior Subordinated Notes due 2019	$	173,635		$	165,296
	Secured Convertible Notes due 2015	94,207			99,851
	Silicon Valley Bank term loan	80,000			80,000
	Silicon Valley Bank line of credit	1,132			2,090
	Total debt	348,974			347,237
	Less: current portion	(95,284		)	(11,762		)
	Long-term debt	$	253,690		$	335,475
Summary Of The Liability Component Of The 2019 Notes	'
	The following is a summary of the liability component of the 2019 Notes (in thousands):
		June 30,			December 31,
		2014			2013
	Net carrying amount of the liability component	$	173,635		$	165,296
	Unamortized discount of the liability component	113,865			122,204
	Face amount of the 2019 Notes	$	287,500		$	287,500

Common_Stock_And_Warrants_Tabl

Common Stock And Warrants (Tables)	6 Months Ended
	Jun. 30, 2014
Warrants and Rights Note Disclosure [Abstract]	'
Schedule Of Warrants To Purchase Common Stock Outstanding And Exercisable	'
	At June 30, 2014, the following warrants to purchase common stock were outstanding and exercisable:
	Date Issued	Exercise		Expiration Date	Number
		Price per Share			of Shares
	January 22, 2014	$	9.7	January 22, 2016	1,000,000

Fair_Value_Measurements_Fair_V

Fair Value Measurements Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2014
Fair Value Disclosures [Abstract]	'
Schedule Of Fair Value Of Financial Assets Measured On A Recurring Basis	'
	The amounts presented exclude cash, but include investments classified as cash equivalents (in thousands):
		June 30, 2014
		Level 1			Level 2			Level 3		Total
	Financial assets:
	Money market funds	$	49,184		$	—		$	—	$	49,184
	Commercial paper	—			97,856			—		97,856
	Corporate bonds	—			150,974			—		150,974
	U.S. Treasury and government sponsored enterprises	—			26,311			—		26,311
	Municipal bonds	—			24,257			—		24,257
	Total financial assets	$	49,184		$	299,398		$	—	$	348,582
	Financial liabilities:
	Warrants	$	—		$	—		$	908	$	908
	Total financial liabilities	$	—		$	—		$	908	$	908
		December 31, 2013
		Level 1			Level 2			Total
	Money market funds	$	24,813		$	—		$	24,813
	Commercial paper	—			94,682			94,682
	Corporate bonds	—			240,072			240,072
	U.S. Treasury and government sponsored enterprises	—			44,386			44,386
	Municipal bonds	—			6,013			6,013
	Total financial assets	$	24,813		$	385,153		$	409,966
Schedule Of Estimated Fair Value Of Outstanding Debt	'
	The estimated fair values of our financial instruments that are carried at amortized cost for which it is practicable to determine a fair value were as follows (in thousands):
		June 30, 2014						December 31, 2013
		Carrying			Fair Value			Carrying		Fair Value
		Amount						Amount
	2019 Notes	$	173,635		$	245,640		$	165,296	$	339,883
	Silicon Valley Bank term loan	$	80,000		$	79,954		$	80,000	$	79,946
	Silicon Valley Bank line of credit	$	1,132		$	1,132		$	2,090	$	2,090
Schedule of Assumptions Used	'
	The fair value of the 2014 Deerfield Warrants were estimated using the following assumptions, which, except for risk-free interest rate, are Level 3 inputs (dollars in thousands):
					22-Jan-14
		June 30, 2014			(issuance date)
	Fair value of warrants	$	908		$	2,762
	Risk-free interest rate	0.98		%	0.95		%
	Dividend yield	—		%	—		%
	Volatility	81		%	57		%
	Average expected life	2.8 years			3.2 years

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2014
Share-based Compensation [Abstract]	'
Schedule Of Allocated Employee Stock-Based Compensation Expenses	'
	We recorded and allocated employee stock-based compensation expenses for our equity incentive plans and our 2000 Employee Stock Purchase Plan (“ESPP”) as follows (in thousands):
		Three Months Ended June 30,								Six Months Ended June 30,
		2014				2013				2014			2013
	Research and development expense	$	1,471			$	1,553			$	3,036		$	2,960
	Selling, general and administrative expense	2,511				1,370				4,704			2,638
	Total employee stock-based compensation expense	$	3,982			$	2,923			$	7,740		$	5,598
Schedule Of Fair Value Of Employee Share-Based Payments Awards Estimated Using The Assumptions And Weighted Average Fair Values	'
	The fair value of employee stock option awards and ESPP purchases was estimated using the following assumptions and weighted average fair values:
		Stock Options
		Three Months Ended June 30,								Six Months Ended June 30,
		2014				2013				2014			2013
	Weighted average grant-date fair value	$	2.33			$	2.56			$	3.65		$	2.52
	Risk-free interest rate	1.75		%		0.98		%		1.66		%	0.92		%
	Dividend yield	—		%		—		%		—		%	—		%
	Volatility	80		%		62		%		81		%	62		%
	Expected life	5.8 years				5.6 years				5.6 years			5.5 years
		Employee Stock Purchase Plan
		Three Months Ended June 30,								Six Months Ended June 30,
		2014				2013				2014			2013
	Weighted average grant-date fair value	$	1.32			$	1.65			$	1.44		$	1.63
	Risk-free interest rate	0.06		%		0.12		%		0.07		%	0.13		%
	Dividend yield	—		%		—		%		—		%	—		%
	Volatility	67		%		67		%		64		%	67		%
	Expected life	6 months				6 months				6 months			6 months
Summary Of All Stock Option Activity	'
	A summary of all stock option activity for the six months ended June 30, 2014 is presented below (dollars in thousands, except per share amounts):
		Shares			Weighted				Weighted		Aggregate
					Average				Average		Intrinsic
					Exercise Price				Remaining Contractual		Value
									Term
	Options outstanding at December 31, 2013	23,983,275			$	6.48
	Granted	1,120,530			$	5.4
	Exercised	(19,090	)		$	6.28
	Forfeited	(166,405	)		$	5.52
	Expired	(423,467	)		$	7.85
	Options outstanding at June 30, 2014	24,494,843			$	6.41			4.30 years		$	37
	Exercisable at June 30, 2014	14,527,591			$	7.05			3.21 years		$	2
Summary Of All RSU Activity	'
	A summary of all restricted stock unit (“RSU”) activity for the six months ended June 30, 2014 is presented below (dollars in thousands, except per share amounts):
		Shares			Weighted				Weighted		Aggregate
					Average				Average		Intrinsic
					Grant Date				Remaining		Value
					Fair Value				Contractual
									Term
	Awards outstanding at December 31, 2013	1,810,521			$	5.56
	Awarded	61,842			$	5.19
	Released	(101,600	)		$	6.78
	Forfeited	(62,540	)		$	5.52
	Awards outstanding at June 30, 2014	1,708,223			$	5.48			2.96 years		$	5,928

Net_Loss_Per_Share_Tables

Net Loss Per Share (Tables)	6 Months Ended
	Jun. 30, 2014
Earnings Per Share [Abstract]	'
Schedule Of Reconciliation Of Basic And Diluted Net Income (Loss) Per Share	'
	The following table sets forth a reconciliation of basic and diluted net loss per share (in thousands, except per share amounts):
		Three Months Ended June 30,							Six Months Ended June 30,
		2014				2013			2014			2013
	Numerator:
	Net loss	$	(73,410	)		$	(62,161	)	$	(148,029	)	$	(106,890	)
	Denominator:
	Shares used in computing basic and diluted net loss per share	194,929				183,981			193,323			183,861
	Net loss per share, basic and diluted	$	(0.38	)		$	(0.34	)	$	(0.77	)	$	(0.58	)
Schedule Of Potential Shares Of Common Stock Not Included In Computation Of Diluted Net Loss Per Share	'
	The following table sets forth outstanding potential shares of common stock that are not included in the computation of diluted net loss per share because, to do so would be anti-dilutive (in thousands):
		June 30
		2014			2013
	Convertible debt	54,123			54,123
	Outstanding stock options, unvested RSUs and ESPP contributions	26,308			18,147
	Warrants	1,000			1,441
	Total potentially dilutive shares	81,431			73,711

Concentrations_of_Credit_Risk_

Concentrations of Credit Risk (Tables)	6 Months Ended
	Jun. 30, 2014
Risks and Uncertainties [Abstract]	'
Schedules of concentration risk	'
	The following table shows the percentage of revenues earned in the United States. The remainder of our revenues were earned in the European Union.
		Three Months Ended June 30,				Six Months Ended June 30,
		2014		2013		2014		2013
	Percentage of revenues earned in the United States	93	%	98	%	96	%	99	%
	The following table sets forth the percentage of revenues recognized under our collaboration agreements and product sales to the specialty pharmacy that represent 10% or more of total revenues during the three and six months ended June 30, 2014 and 2013:
		Three Months Ended June 30,				Six Months Ended June 30,
		2014		2013		2014		2013
	Collaboration agreement:
	Bristol-Myers Squibb	—	%	66	%	—	%	73	%
	Product sales:
	Diplomat Specialty Pharmacy	93	%	32	%	96	%	26	%

Organization_and_Summary_of_Si2

Organization and Summary of Significant Accounting Policies (Details)	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
	segment
	trial
Operations [Line Items]	'	'
Number of trials in process with expected results in current fiscal year	2	'
Number of trials in process	5	'
Operating cycle	'371 days	'364 days
Number of operating segments	1	'
Glaxo Smith Kline [Member]	'	'
Operations [Line Items]	'	'
Percent of royalty on net sale	3.00%	'
Minimum [Member]	'	'
Operations [Line Items]	'	'
Operating cycle	'364 days	'
Maximum [Member]	'	'
Operations [Line Items]	'	'
Operating cycle	'371 days	'

Restructurings_Narrative_Detai

Restructurings (Narrative) (Details) (USD $)	3 Months Ended		6 Months Ended		12 Months Ended	52 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013	Jun. 30, 2014	Dec. 31, 2012
	employee		employee			restructuring
						employee
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'	'
Number of restructurings implemented	'	'	'	'	'	5	'
Aggregate reduction in headcount	429	'	429	'	'	429	'
Restructuring charge (credit)	$331,000	$609,000	$377,000	$728,000	$1,231,000	$53,700,000	'
Restructuring reserve	10,469,000	'	10,469,000	'	13,472,000	10,469,000	19,222,000
Expected additional payment for restructuring	'	'	1,100,000	'	'	'	'
Restructuring reserve, settled with cash	'	'	3,502,000	'	6,765,000	38,700,000	'
Proceeds from subtenants	'	'	'	'	'	12,200,000	'
Proceeds from sale of property and equipment	'	'	281,000	0	'	'	'
Restructuring reserve, cash settlement net of proceeds	'	'	3,300,000	4,000,000	'	'	'
Facility Closing [Member]	'	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'	'
Restructuring charge (credit)	'	'	490,000	'	662,000	29,700,000	'
Restructuring reserve	10,463,000	'	10,463,000	'	13,460,000	10,463,000	19,202,000
Restructuring reserve, settled with cash	'	'	3,496,000	'	6,331,000	'	'
Termination Benefits [Member]	'	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'	'
Restructuring charge (credit)	'	'	'	'	'	21,700,000	'
Asset Impairment [Member]	'	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'	'
Restructuring charge (credit)	'	'	-100,000	'	'	2,200,000	'
Proceeds from sale of property and equipment	'	'	'	'	'	$2,900,000	'

Restructurings_Summary_of_Comp

Restructurings (Summary of Components of Restructuring Liability) (Details) (USD $)	3 Months Ended		6 Months Ended		12 Months Ended	52 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013	Jun. 30, 2014
Restructuring Reserve [Roll Forward]	'	'	'	'	'	'
Restructuring liability	'	'	$13,472	$19,222	$19,222	'
Restructuring charge (credit)	331	609	377	728	1,231	53,700
Cash payments	'	'	-3,502	'	-6,765	-38,700
Adjustments or non-cash credits	'	'	-77	'	-311	'
Proceeds from sale of assets	'	'	199	'	95	'
Restructuring liability	10,469	'	10,469	'	13,472	10,469
Facility Charges [Member]	'	'	'	'	'	'
Restructuring Reserve [Roll Forward]	'	'	'	'	'	'
Restructuring liability	'	'	13,460	19,202	19,202	'
Restructuring charge (credit)	'	'	490	'	662	29,700
Cash payments	'	'	-3,496	'	-6,331	'
Adjustments or non-cash credits	'	'	9	'	-73	'
Proceeds from sale of assets	'	'	0	'	0	'
Restructuring liability	10,463	'	10,463	'	13,460	10,463
Other [Member]	'	'	'	'	'	'
Restructuring Reserve [Roll Forward]	'	'	'	'	'	'
Restructuring liability	'	'	12	20	20	'
Restructuring charge (credit)	'	'	-113	'	569	'
Cash payments	'	'	-6	'	-434	'
Adjustments or non-cash credits	'	'	-86	'	-238	'
Proceeds from sale of assets	'	'	199	'	95	'
Restructuring liability	$6	'	$6	'	$12	$6

Cash_and_Investments_Cash_and_1

Cash and Investments Cash and Investments (Details) (USD $)	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013
	account
	affiliate
	investment
Schedule of Available-for-sale Securities [Line Items]	'	'	'
Amortized Cost	$351,743,000	'	$415,617,000
Gross Unrealized Gains	315,000	'	300,000
Gross Unrealized Losses	-33,000	'	-55,000
Fair Value	352,025,000	'	415,862,000
Debt collateral, number of required investment accounts	1	'	'
Debt collateral, number of affiliate banks	1	'	'
Amortized Cost	348,300,000	'	409,721,000
Gross Unrealized Gains	315,000	'	300,000
Gross Unrealized Losses	-33,000	'	-55,000
Fair Value	348,582,000	'	409,966,000
Gain (loss) on sale of investments	0	0	'
Number of investments in an unrealized loss position, less than 1 year	25	'	'
Unrealized loss position, less than 1 year	50,100,000	'	'
Number of investments in an unrealized loss position, greater than 1 year	0	'	'
Unrealized loss position, greater than 1 year	0	'	'
Mature within One Year	302,961,000	'	'
After One Year through Two Years	45,621,000	'	'
Money market funds [Member]	'	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'	'
Amortized Cost	49,184,000	'	24,813,000
Gross Unrealized Gains	0	'	0
Gross Unrealized Losses	0	'	0
Fair Value	49,184,000	'	24,813,000
Mature within One Year	49,184,000	'	'
After One Year through Two Years	0	'	'
Commercial paper [Member]	'	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'	'
Amortized Cost	97,856,000	'	94,682,000
Gross Unrealized Gains	0	'	0
Gross Unrealized Losses	0	'	0
Fair Value	97,856,000	'	94,682,000
Mature within One Year	97,856,000	'	'
After One Year through Two Years	0	'	'
Corporate bonds [Member]	'	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'	'
Amortized Cost	150,828,000	'	239,937,000
Gross Unrealized Gains	178,000	'	190,000
Gross Unrealized Losses	-32,000	'	-55,000
Fair Value	150,974,000	'	240,072,000
Mature within One Year	111,449,000	'	'
After One Year through Two Years	39,525,000	'	'
U.S. Treasury and government sponsored enterprises [Member]	'	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'	'
Amortized Cost	26,186,000	'	44,284,000
Gross Unrealized Gains	126,000	'	102,000
Gross Unrealized Losses	-1,000	'	0
Fair Value	26,311,000	'	44,386,000
Mature within One Year	20,215,000	'	'
After One Year through Two Years	6,096,000	'	'
Municipal bonds [Member]	'	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'	'
Amortized Cost	24,246,000	'	6,005,000
Gross Unrealized Gains	11,000	'	8,000
Gross Unrealized Losses	0	'	'
Fair Value	24,257,000	'	6,013,000
Mature within One Year	24,257,000	'	'
After One Year through Two Years	0	'	'
Silicon Valley Bank Loan And Security Agreement [Member]	'	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'	'
Collateral balance	82,800,000	'	83,700,000
Cash and cash equivalents [Member]	'	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'	'
Amortized Cost	147,339,000	'	103,978,000
Gross Unrealized Gains	2,000	'	0
Gross Unrealized Losses	-1,000	'	0
Fair Value	147,340,000	'	103,978,000
Short-term investments [Member]	'	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'	'
Amortized Cost	86,046,000	'	138,403,000
Gross Unrealized Gains	140,000	'	94,000
Gross Unrealized Losses	-9,000	'	-22,000
Fair Value	86,177,000	'	138,475,000
Short-term restricted cash and investments [Member]	'	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'	'
Amortized Cost	12,143,000	'	12,173,000
Gross Unrealized Gains	71,000	'	40,000
Gross Unrealized Losses	0	'	0
Fair Value	12,214,000	'	12,213,000
Long-term investments [Member]	'	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'	'
Amortized Cost	95,489,000	'	144,226,000
Gross Unrealized Gains	47,000	'	106,000
Gross Unrealized Losses	-23,000	'	-33,000
Fair Value	95,513,000	'	144,299,000
Long-term restricted cash and investments [Member]	'	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'	'
Amortized Cost	10,726,000	'	16,837,000
Gross Unrealized Gains	55,000	'	60,000
Gross Unrealized Losses	0	'	0
Fair Value	$10,781,000	'	$16,897,000

Inventory_Details

Inventory (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Inventory Disclosure [Abstract]	'	'
Raw materials	$643	$529
Work in process	1,871	2,280
Finished goods	512	81
Total	$3,026	$2,890	[1]
[1]	The condensed consolidated balance sheet as of December 31, 2013 has been derived from the audited financial statements as of that date.

Debt_Schedule_Of_Debt_Details

Debt (Schedule Of Debt) (Details) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013
Debt Instrument [Line Items]	'	'	'	'	'
Total debt	$348,974	'	$348,974	'	$347,237
Less: current portion	-95,284	'	-95,284	'	-11,762
Long-term debt	253,690	'	253,690	'	335,475
Senior Subordinated Notes [Member] | 4.25% Convertible Senior Subordinated Notes due August 15, 2019 [Member]	'	'	'	'	'
Debt Instrument [Line Items]	'	'	'	'	'
Stated coupon interest	3,054	3,054	6,143	6,109	'
Convertible Debt	173,635	'	173,635	'	165,296
Amortization of debt discount and debt issuance costs	4,397	4,001	8,692	7,910	'
Interest Expense, Debt	7,451	7,055	14,835	14,019	'
Secured Debt [Member] | Deerfield Notes [Member]	'	'	'	'	'
Debt Instrument [Line Items]	'	'	'	'	'
Convertible Debt	94,207	'	94,207	'	99,851
Term Loan [Member] | Silicon Valley Bank term loan and Line of Credit [Member]	'	'	'	'	'
Debt Instrument [Line Items]	'	'	'	'	'
Silicon Valley Bank term loan	80,000	'	80,000	'	80,000
Line of Credit [Member] | Silicon Valley Bank term loan and Line of Credit [Member]	'	'	'	'	'
Debt Instrument [Line Items]	'	'	'	'	'
Silicon Valley Bank Line of Credit	$1,132	'	$1,132	'	$2,090

Debt_Convertible_Notes_Details

Debt (Convertible Notes) (Details) (USD $)

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Dec. 31, 2013

Aug. 14, 2012

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Dec. 31, 2013

Jun. 30, 2010

Senior Subordinated Notes [Member]

Senior Subordinated Notes [Member]

Senior Subordinated Notes [Member]

Senior Subordinated Notes [Member]

Senior Subordinated Notes [Member]

Senior Subordinated Notes [Member]

Secured Convertible Notes Due June 2015 [Member]

Secured Convertible Notes Due June 2015 [Member]

Secured Convertible Notes Due June 2015 [Member]

Secured Convertible Notes Due June 2015 [Member]

Secured Convertible Notes Due June 2015 [Member]

Secured Convertible Notes Due June 2015 [Member]

4.25% Convertible Senior Subordinated Notes due August 15, 2019 [Member]

4.25% Convertible Senior Subordinated Notes due August 15, 2019 [Member]

4.25% Convertible Senior Subordinated Notes due August 15, 2019 [Member]

4.25% Convertible Senior Subordinated Notes due August 15, 2019 [Member]

4.25% Convertible Senior Subordinated Notes due August 15, 2019 [Member]

4.25% Convertible Senior Subordinated Notes due August 15, 2019 [Member]

Deerfield Financing [Member]

Deerfield Financing [Member]

Deerfield Financing [Member]

Deerfield Financing [Member]

Deerfield Financing [Member]

Deerfield Financing [Member]

Debt Instrument [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Net carrying amount of the liability component

$173,635,000

'

$173,635,000

'

$165,296,000

'

$104,000,000

'

$104,000,000

'

$114,000,000

'

Unamortized discount of the liability component

113,865,000

'

113,865,000

'

122,204,000

'

'

'

'

'

'

'

Face amount

287,500,000

'

287,500,000

'

287,500,000

287,500,000

'

'

'

'

'

124,000,000

Stated coupon interest

3,054,000

3,054,000

6,143,000

6,109,000

'

'

1,495,000

1,496,000

2,975,000

2,975,000

'

'

Amortization of debt discount and debt issuance costs

4,397,000

4,001,000

8,692,000

7,910,000

'

'

2,931,000

2,478,000

5,626,000

4,883,000

'

'

Total interest expense

$7,451,000

$7,055,000

$14,835,000

$14,019,000

'

'

$4,426,000

$3,974,000

$8,601,000

$7,858,000

'

'

Debt_Narrative_Details

Debt (Narrative) (Details) (USD $)

0 Months Ended

Jan. 22, 2014

Jan. 22, 2014

Jun. 30, 2014

Jun. 30, 2014

Dec. 31, 2013

Aug. 14, 2012

Jun. 30, 2014

Jan. 22, 2014

Dec. 31, 2013

Jun. 30, 2010

Jan. 22, 2014

Jan. 22, 2014

Issued On January 22, 2014 [Member]

Issued On January 22, 2014 [Member]

Issued On January 22, 2014 [Member]

Senior Subordinated Notes [Member]

Senior Subordinated Notes [Member]

Senior Subordinated Notes [Member]

Secured Convertible Notes Due June 2015 [Member]

Secured Convertible Notes Due June 2015 [Member]

Secured Convertible Notes Due June 2015 [Member]

Secured Convertible Notes Due June 2015 [Member]

Secured Convertible Notes Due June 2015 [Member]

Secured Convertible Notes Due June 2015 [Member]

4.25% Convertible Senior Subordinated Notes due August 15, 2019 [Member]

4.25% Convertible Senior Subordinated Notes due August 15, 2019 [Member]

4.25% Convertible Senior Subordinated Notes due August 15, 2019 [Member]

Deerfield Financing [Member]

Deerfield Financing [Member]

Deerfield Financing [Member]

Deerfield Financing [Member]

Deerfield Financing [Member]

Deerfield Financing [Member]

Coupon Interest [Member]

Payment-in-Kind Interest [Member]

Debt Instrument [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Debt, interest rate

'

'

'

'

'

4.25%

'

'

'

'

'

'

Debt, principal amount

'

'

'

$287,500,000

$287,500,000

$287,500,000

'

'

'

$124,000,000

'

'

Balance of unamortized closing fees and expenses

'

'

'

3,600,000

4,000,000

'

2,900,000

'

1,400,000

'

'

'

Convertible debt

'

'

'

173,635,000

165,296,000

'

104,000,000

'

114,000,000

'

'

'

Principal eligible for extension option

'

'

'

'

'

'

'

100,000,000

'

'

'

'

Debt instrument, interest rate, stated percentage after extension option election

'

'

'

'

'

'

'

15.00%

'

'

7.50%

7.50%

Warrant period

'2 years

'2 years

'

'

'

'

'

'

'

'

'

'

Warrants outstanding

'

1,000,000

1,000,000

'

'

'

'

'

'

'

'

'

Warrant exercise price (in dollars per warrant)

'

9.7

9.7

'

'

'

'

'

'

'

'

'

Debt instrument, discount

'

'

'

'

'

'

'

$2,800,000

'

'

'

'

Common_Stock_And_Warrants_Narr

Common Stock And Warrants (Narrative) (Details) (USD $)	1 Months Ended	6 Months Ended		0 Months Ended		3 Months Ended	6 Months Ended
	Jan. 31, 2014	Jun. 30, 2014	Jun. 30, 2013	Jan. 22, 2014	Jan. 22, 2014	Jun. 30, 2014	Jun. 30, 2014
				Issued On January 22, 2014 [Member]	Issued On January 22, 2014 [Member]	Issued On January 22, 2014 [Member]	Issued On January 22, 2014 [Member]
Class of Warrant or Right [Line Items]	'	'	'	'	'	'	'
Public offering of common stock	10,000,000	'	'	'	'	'	'
Share price (dollars per share)	$8	'	'	'	'	'	'
Net proceeds from public offering	$75,600,000	$75,646,000	$0	'	'	'	'
Warrants outstanding	'	'	'	'	1,000,000	1,000,000	1,000,000
Warrant exercise price (in dollars per warrant)	'	'	'	'	9.7	9.7	9.7
Warrant period	'	'	'	'2 years	'2 years	'	'
Warrant repricing terms on exercise of extension option	'	'	'	'	120.00%	'	'
Fair value of warrants	'	'	'	'	2,800,000	900,000	900,000
Unrealized gain on warrants	'	'	'	'	'	$100,000	$1,900,000

Common_Stock_And_Warrants_Sche

Common Stock And Warrants (Schedule Of Warrants To Purchase Common Stock Outstanding And Exercisable) (Details) (Issued On January 22, 2014 [Member])	6 Months Ended
	Jun. 30, 2014	Jan. 22, 2014
Issued On January 22, 2014 [Member]	'	'
Class of Warrant or Right [Line Items]	'	'
Exercise Price per Share	9.7	9.7
Expiration Date	'1/22/2016	'
Number of Shares	1,000,000	1,000,000

Fair_Value_Measurements_Schedu

Fair Value Measurements (Schedule Of Fair Value Of Financial Assets Measured On A Recurring Basis) (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total fair value of financial assets	$348,582	$409,966
Warrants	908	'
Total financial liabilities	908	'
Level 1 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total fair value of financial assets	49,184	24,813
Warrants	0	'
Total financial liabilities	0	'
Level 2 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total fair value of financial assets	299,398	385,153
Warrants	0	'
Total financial liabilities	0	'
Level 3 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total fair value of financial assets	0	'
Warrants	908	'
Total financial liabilities	908	'
Money market funds [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total fair value of financial assets	49,184	24,813
Money market funds [Member] | Level 1 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total fair value of financial assets	49,184	24,813
Money market funds [Member] | Level 2 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total fair value of financial assets	0	0
Money market funds [Member] | Level 3 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total fair value of financial assets	0	'
Commercial paper [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total fair value of financial assets	97,856	94,682
Commercial paper [Member] | Level 1 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total fair value of financial assets	0	0
Commercial paper [Member] | Level 2 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total fair value of financial assets	97,856	94,682
Commercial paper [Member] | Level 3 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total fair value of financial assets	0	'
Corporate bonds [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total fair value of financial assets	150,974	240,072
Corporate bonds [Member] | Level 1 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total fair value of financial assets	0	0
Corporate bonds [Member] | Level 2 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total fair value of financial assets	150,974	240,072
Corporate bonds [Member] | Level 3 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total fair value of financial assets	0	'
U.S. Treasury and government sponsored enterprises [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total fair value of financial assets	26,311	44,386
U.S. Treasury and government sponsored enterprises [Member] | Level 1 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total fair value of financial assets	0	0
U.S. Treasury and government sponsored enterprises [Member] | Level 2 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total fair value of financial assets	26,311	44,386
U.S. Treasury and government sponsored enterprises [Member] | Level 3 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total fair value of financial assets	0	'
Municipal bonds [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total fair value of financial assets	24,257	6,013
Municipal bonds [Member] | Level 1 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total fair value of financial assets	0	0
Municipal bonds [Member] | Level 2 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total fair value of financial assets	24,257	6,013
Municipal bonds [Member] | Level 3 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total fair value of financial assets	$0	'

Fair_Value_Measurements_Schedu1

Fair Value Measurements (Schedule of Estimated Fair Value of Outstanding Debt) (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Carrying Amount [Member] | Senior Subordinated Notes [Member] | 4.25% Convertible Senior Subordinated Notes due August 15, 2019 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Fair values of financial instruments	$173,635	$165,296
Carrying Amount [Member] | Term Loan [Member] | Silicon Valley Bank term loan and Line of Credit [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Fair values of financial instruments	80,000	80,000
Carrying Amount [Member] | Line of Credit [Member] | Silicon Valley Bank term loan and Line of Credit [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Fair values of financial instruments	1,132	2,090
Fair Value [Member] | Senior Subordinated Notes [Member] | 4.25% Convertible Senior Subordinated Notes due August 15, 2019 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Fair values of financial instruments	245,640	339,883
Fair Value [Member] | Term Loan [Member] | Silicon Valley Bank term loan and Line of Credit [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Fair values of financial instruments	79,954	79,946
Fair Value [Member] | Line of Credit [Member] | Silicon Valley Bank term loan and Line of Credit [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Fair values of financial instruments	$1,132	$2,090

Fair_Value_Measurements_Schedu2

Fair Value Measurements (Schedule of Assumptions Used) (Details) (Issued On January 22, 2014 [Member], USD $)	0 Months Ended			6 Months Ended
In Thousands, unless otherwise specified	Jan. 22, 2014	Jan. 22, 2014	Jan. 22, 2014	Jun. 30, 2014
			Warrant liability [Member]	Warrant liability [Member]
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]	'	'	'	'
Warrant period	'2 years	'2 years	'	'
Fair value of warrants	'	'	'	$908
Risk-free interest rate	'	'	0.95%	0.98%
Dividend yield	'	'	0.00%	0.00%
Volatility	'	'	57.00%	81.00%
Average expected life	'	'	'3 years 2 months 12 days	'2 years 9 months 18 days

StockBased_Compensation_Schedu

Stock-Based Compensation (Schedule of Allocated Employee Stock-Based Compensation Expenses) (Details) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Total employee stock-based compensation expense	$3,982	$2,923	$7,740	$5,598
Research and development expense [Member]	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Total employee stock-based compensation expense	1,471	1,553	3,036	2,960
Selling, general and administrative expense [Member]	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Total employee stock-based compensation expense	$2,511	$1,370	$4,704	$2,638

StockBased_Compensation_Schedu1

Stock-Based Compensation (Schedule of Fair Value of Employee Share-Based Payments Awards Estimated Using the Assumptions and Weighted Average Fair Values) (Details) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Employee Stock Option [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Weighted average grant date fair value	$2.33	$2.56	$3.65	$2.52
Risk-free interest rate	1.75%	0.98%	1.66%	0.92%
Dividend yield	0.00%	0.00%	0.00%	0.00%
Volatility	80.00%	62.00%	81.00%	62.00%
Expected life	'5 years 9 months 10 days	'5 years 7 months 6 days	'5 years 7 months 13 days	'5 years 6 months
Employee Stock Purchase Plan [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Weighted average grant date fair value	$1.32	$1.65	$1.44	$1.63
Risk-free interest rate	0.06%	0.12%	0.07%	0.13%
Dividend yield	0.00%	0.00%	0.00%	0.00%
Volatility	67.00%	67.00%	64.00%	67.00%
Expected life	'6 months	'6 months	'6 months	'6 months

StockBased_Compensation_Narrat

Stock-Based Compensation (Narrative) (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013	Jun. 30, 2014	Jun. 30, 2014	Jun. 30, 2014
In Millions, except Share data, unless otherwise specified			Performance Stock Options [Member]	Employee Stock Option [Member]	Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'
Options outstanding, in shares	24,494,843	23,983,275	3,640,752	'	'
Grant date fair value	'	'	$6.70	'	'
Unrecognized compensation expense	'	'	'	$16.60	$6.20
Unrecognized compensation expense, weighted-average period for recognition (in years)	'	'	'	'2 years 3 months 18 days	'2 years 11 months 15 days

StockBased_Compensation_Summar

Stock-Based Compensation (Summary of All Stock Option Activity) (Details) (USD $)	6 Months Ended
In Thousands, except Share data, unless otherwise specified	Jun. 30, 2014
Shares [Roll Forward]	'
Options outstanding at beginning of period, Shares	23,983,275
Granted, Shares	1,120,530
Exercised, Shares	-19,090
Forfeited, Shares	-166,405
Expired, Shares	-423,467
Options outstanding at end of period, Shares	24,494,843
Exercisable at end of period, Shares	14,527,591
Weighted Average Exercise Price [Roll Forward]	'
Options outstanding at beginning of period, Weighted Average Exercise Price	$6.48
Granted, Weighted Average Exercise Price	$5.40
Exercised, Weighted Average Exercise Price	$6.28
Forfeited, Weighted Average Exercise Price	$5.52
Expired, Weighted Average Exercise Price	$7.85
Options outstanding at end of period, Weighted Average Exercise Price	$6.41
Exercisable at end of period, Weighted Average Exercise Price	$7.05
Options outstanding at end of period, Weighted Average Remaining Contractual Term	'4 years 3 months 18 days
Exercisable at end of period, Weighted Average Remaining Contractual Term	'3 years 2 months 15 days
Options outstanding at end of period, Aggregate Intrinsic Value, in dollars	$37
Exercisable at end of period, Aggregate Intrinsic Value, in dollars	$2

StockBased_Compensation_Summar1

Stock-Based Compensation (Summary of All RSU Activity) (Details) (Restricted Stock Units (RSUs) [Member], USD $)	6 Months Ended
In Thousands, except Share data, unless otherwise specified	Jun. 30, 2014
Restricted Stock Units (RSUs) [Member]	'
Shares [Roll Forward]	'
RSUs outstanding at beginning of period, Shares	1,810,521
Awarded, Shares	61,842
Released, Shares	-101,600
Forfeited, Shares	-62,540
RSUs outstanding at end of period, Shares	1,708,223
Weighted Average Grant DateFair Value [Roll Forward]	'
RSUs outstanding at beginning of period, Weighted Average Grant Date Fair Value	$5.56
Awarded, Weighted Average Grant Date Fair Value	$5.19
Released, Weighted Average Grant Date Fair Value	$6.78
Forfeited, Weighted Average Grant Date Fair Value	$5.52
RSUs outstanding at end of period, Weighted Average Grant Date Fair Value	$5.48
RSUs outstanding at end of period, Weighted Average Remaining Contractual Term	'2 years 11 months 15 days
RSUs outstanding at end of period, Aggregate Intrinsic Value, in dollars	$5,928

Net_Loss_Per_Share_Details

Net Loss Per Share (Details) (USD $)	3 Months Ended		6 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Net loss, in dollars	($73,410)	($62,161)	($148,029)	($106,890)
Shares used in computing basic and diluted net loss per share	194,929	183,981	193,323	183,861
Net loss per share, basic and diluted, in dollars per share	($0.38)	($0.34)	($0.77)	($0.58)
Potentially dilutive shares	'	'	81,431	73,711
Convertible debt [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Potentially dilutive shares	'	'	54,123	54,123
Outstanding stock options, unvested RSUs and ESPP contributions [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Potentially dilutive shares	'	'	26,308	18,147
Warrants [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Potentially dilutive shares	'	'	1,000	1,441

Concentrations_of_Credit_Risk_1

Concentrations of Credit Risk (Details)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Revenue from Rights Concentration Risk [Member] | Accounts Receivable [Member] | European Distribution Partner [Member]	'	'	'	'
Concentration Risk [Line Items]	'	'	'	'
Concentration risk, percentage	'	'	12.00%	'
Revenue from Rights Concentration Risk [Member] | Accounts Receivable [Member] | Diplomat Specialty Pharmacy [Member]	'	'	'	'
Concentration Risk [Line Items]	'	'	'	'
Concentration risk, percentage	'	'	78.00%	'
Revenue from Rights Concentration Risk [Member] | Revenue, Rights Granted [Member] | Bristol-Myers Squibb [Member]	'	'	'	'
Concentration Risk [Line Items]	'	'	'	'
Concentration risk, percentage	0.00%	66.00%	0.00%	73.00%
Revenue from Rights Concentration Risk [Member] | Sales Revenue, Goods, Net [Member] | Diplomat Specialty Pharmacy [Member]	'	'	'	'
Concentration Risk [Line Items]	'	'	'	'
Concentration risk, percentage	93.00%	32.00%	96.00%	26.00%
UNITED STATES | Geographic Concentration Risk [Member] | Sales [Member]	'	'	'	'
Concentration Risk [Line Items]	'	'	'	'
Concentration risk, percentage	93.00%	98.00%	96.00%	99.00%